Biperiden

Biperiden

SCHEMBL34957

OC(CCN1CCCCC1)(c1ccccc1)C1CC2C=CC1C2

nearest known ligand 1.00 ✓ in ChEMBL — recovers established targets

Full drug profile on Sugi Atlas →

Known targets — ChEMBL curated mechanism

CHRM1

The experimentally established mechanism targets of Biperiden. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CHRM1 known ✓ P11229 7/20 1.00
CYP2D6 P10635 7/20 1.00
CHRM2 P08172 7/20 1.00
CHRM3 P20309 6/20 1.00
KCNH2 Q12809 5/20 1.00
CHRM4 P08173 5/20 1.00
LMNA P02545 3/20 1.00
CYP3A4 P08684 2/20 1.00
HRH1 P35367 2/20 1.00
HIF1A Q16665 1/20 1.00
PTGS2 P35354 1/20 1.00
HRH3 Q9Y5N1 1/20 1.00
CHRM5 P08912 4/20 0.61
HTR1A P08908 3/20 0.61
OPRM1 P35372 3/20 0.61
SIGMAR1 Q99720 2/20 0.61
GRIN2D O15399 1/20 0.61
GRIN3B O60391 1/20 0.61
GRIN1 Q05586 1/20 0.61
GRIN2A Q12879 1/20 0.61

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Biperiden SCHEMBL20229360 1.00 CYP2D6 (1.00) CYP2D6CHRM2CHRM1CHRM3KCNH2
Biperiden SCHEMBL20229362 1.00 CYP2D6 (1.00) CYP2D6CHRM2CHRM1CHRM3KCNH2
Biperiden SCHEMBL20211718 1.00 CYP2D6 (1.00) CYP2D6CHRM2CHRM1CHRM3KCNH2
Biperiden SCHEMBL6775788 1.00 CYP2D6 (1.00) CYP2D6CHRM2CHRM1CHRM3KCNH2
Biperiden SCHEMBL16449749 1.00 CYP2D6 (1.00) CYP2D6CHRM2CHRM1CHRM3KCNH2
Biperiden SCHEMBL13898507 1.00 CYP2D6 (1.00) CYP2D6CHRM2CHRM1CHRM3KCNH2
Biperiden SCHEMBL23697535 1.00 CYP2D6 (1.00) CYP2D6CHRM2CHRM1CHRM3KCNH2
Biperiden SCHEMBL18281117 1.00 CYP2D6 (1.00) CYP2D6CHRM2CHRM1CHRM3KCNH2
Biperiden SCHEMBL16449751 1.00 CYP2D6 (1.00) CYP2D6CHRM2CHRM1CHRM3KCNH2
Biperiden SCHEMBL18281119 1.00 CYP2D6 (1.00) CYP2D6CHRM2CHRM1CHRM3KCNH2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Appears in 11690 patents — a generic fragment claimed broadly, so it's down-weighted as IP noise. Top by claim status then date:

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3607938-B1 PHARMACEUTICAL COMPOSITION SOVIC BRKICIC LJILJANA (HR) 2026-05-27 EP claimed
WO-2026100654-A1 NUCLEIC ACID INTRODUCTION AID, NUCLEIC ACID INTRODUCTION AGENT, AND NUCLEIC ACID INTRODUCTION METHOD 株式会社インファーマシア 2026-05-15 WO claimed
EP-4724049-A1 MODIFIED RELEASE FILL COMPOSITIONS FOR DOSAGE FORMS AND METHODS OF PREPARATION AND USE THEREOF Catalent Ontario Limited (CA) 2026-04-15 EP claimed
US-12550885-B2 Red blood cell storage solutions, solution additives, and methods for improving the storage of red blood cells UNIVERSITY OF CINCINNATI (US) 2026-02-17 US claimed
US-20260027178-A1 Treatment Of Parkinson's Disease With SIM BHLH Transcription Factor 2 (SIM2) Agonists REGENERON PHARMA (US) 2026-01-29 US claimed
EP-3507371-B1 COMPOSITIONS FOR TREATING DISEASES AND DISORDERS OF THE NERVOUS SYSTEM UNIV RUTGERS (US) 2026-01-28 EP claimed
EP-4673215-A1 GBA1 AND GCS DUAL MODULATOR ONO Pharmaceutical Co., Ltd. (JP) 2026-01-07 EP claimed
US-12514856-B2 Pediatric trazodone compositions and method of treatment thereof ANGELINI S.P.A. (IT) 2026-01-06 US claimed
US-20260000910-A1 METHOD FOR TREATING PARKINSON'S DISEASE THROUGH PHOTOSTIMULATION, AND DEVICE USED IN SAID METHOD TSUBOTA LAB INC (JP) 2026-01-01 US claimed
EP-4658278-A1 SELECTIVE FIASMA TREATMENT Valo Health, Inc. (US) 2025-12-10 EP claimed
US-5039528-A EAA antagonists as anti-emetic drugs OLNEY JOHN W (US) 1991-08-13 US claimed
US-5034400-A N-methyl-D-aspartate antagonist for side effect reduction OLNEY JOHN W (US) 1991-07-23 US claimed
EP-0432994-A2 Excitatory amino acid antagonists as anti-emetic drugs Olney, John William (US) 1991-06-19 EP claimed
EP-0424179-A2 Use of combined excitatory amino acid and cholinergic antagonists to prevent neurological deterioration Olney, John William (US) 1991-04-24 EP claimed
US-4996047-A Sustained release drug-resin complexes RICHARDSON-VICKS, INC. (US) 1991-02-26 US claimed
US-4988710-A Anticonvulsants, anticholinergic agents, aryl-cycloalkanolamines WASHINGTON UNIVERSITY (US) 1991-01-29 US claimed
EP-0380989-A2 Plaster for transdermal administration KNOLL AG (DE) 1990-08-08 EP claimed
US-4945097-A THERAPY FOR ANOXIA, HYPOXIA, OR ISCHEMIA G. D. SEARLE & CO. (US) 1990-07-31 US claimed
EP-0367746-A2 Sustained release drug-resin complexes RICHARDSON-VICKS, INC. (US) 1990-05-09 EP claimed
US-4863738-A TRANSDERMAL DRUG DELIVERY ALZA CORPORATION (US) 1989-09-05 US claimed